Bortezomib (Velcade~R) to Deplete Plasma Cells and Remove HLA Antibodies EVENING SESSION II

摘要

In 1969, Patel and Terasaki showed the correlation between the lymphocyte crossmatch and allograft rejection, i.e., rejection in the presence of a positive cytotoxic crossmatch. In the complement-dependent cytotoxic (CDC) lymphocyte assay, cell death resulted from complement-fixing antibodies. The current solid phase antibody screening assays are HLA and IgG-specific, but detect both complement fixing and non-fixing antibodies. However, it is the antibodies that fix complement that are clinically relevant in transplant.